natgillin/translations-raw huggingface dataset:
Only healthy animals should be vaccinated. 
Cepite le zdrave živali.
4.2 Indications for use, specifying the target species 
4.2 Indikacije za uporabo opredelitev ciljne živalske vrste
After inoculation, the viruses do not multiply in the horse but express the protective proteins. 
Po inokulaciji se virusi v konjih ne razmnožujejo, ampak izražajo zaščitne proteine, ki spodbudijo imunost proti virusu konjske influence (H3N8).
In case of increased infection risk or insufficient colostrum intake, an additional initial injection of ProteqFlu-Te can be given at the age of 4 months followed by the full vaccination programme (primary vaccination course at 5-6 months of age and 4-6 weeks later followed by revaccination). 
V primeru povečanega tveganja okužbe ali nezadostnega zaužitja kolostruma se lahko injicira dodaten začetni odmerek Proteqflu TE v starosti štirih mesecev, ki mu sledi popoln program cepljenja (prvi odmerek v starosti petih do šestih mesecev, drugi odmerek 4 do 6 tednov pozneje, sledi revakcinacija).
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial 
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
• 5 months after primary vaccination course with ProteqFlu-Te. 
• 5 mesecev po primarnem cepljenju.
Marketing authorisation holder: Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein GERMANY 
Imetnik dovoljenja za promet z zdravilom : Boehringer Ingelheim Vetmedica GmbH 55216 Ingelheim/Rhein
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 
- Redki (pojavijo se pri 1 od 10 živali od 10.000 živali) - Zelo redki (pojavijo se pri manj kot 1 živali od 10.000 živali, vključujoč posamezne primere).
Shake the vaccine gently before use. 
Cepivo pred uporabo rahlo pretresite.
• Pain, local hyperthermia and muscle stiffness can occur in rare cases. 
• V redkih primerih se lahko pojavijo bolečina, lokalno povišana temperatura in otrdelost mišic.
Incompatibilities: Do not mix with any veterinary medicinal product. 
Inkompatibilnosti: Ne mešajte z nobenim drugim zdravilom razen s priloženim vehiklom.
6.5 Nature and composition of immediate packaging 
6.5 Vrsta in vsebina vsebnika
• Store and transport refrigerated (2 °C - 8 °C). 
• Shranjujte in prevažajte v hladilniku 2 °C 8 °C.
In rare occasions, swelling can reach a diameter up to 15-20 cm, with duration up to 2-3 weeks, 
V redkih primerih se lahko pojavi oteklina s premerom do 15 - 20 cm, ki traja od 2 - 3 tedne in lahko zahteva simptomatsko zdravljenje.
Carbomer ......................................................................................................................................... 4 mg. For the full list of excipients, see section 6.1. 
Karbomer ........................................................................................................................................... 4 mg Celoten seznam pomožnih snovi, glej razdelek 6.1.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION 
ODMEREK ZA POSAMEZNE ŽIVALSKE VRSTE TER NAČIN UPORABE IN
Name and address of the manufacturer responsible for batch release 
Ime in naslov proizvajalca odgovornega za sprostitev serije
STATEMENT OF THE MRLs 
ZDRAVILA (MRL)
Veterinary medicinal product subject to prescription. 
Zdravila za uporabo v veterinarski medicini na recept.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary 
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če so potrebni) Po dajanju prevelikih odmerkov niso ugotovili nobenih drugih stranskih učinkov razen tistih,
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products 
6.6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi, če obstajajo
Intramuscular use 
Intramuskularno dajanje
Administer one dose (1 ml), by intramuscular injection, preferably in the neck region, according to the following schedule: - Primary vaccination course with ProteqFlu-Te: first injection from 5-6 months of age, second injection 4-6 weeks later. 
Injicirajte 1 odmerek (1 ml) intramuskularno, priporočljivo v predel vratu, po naslednjem razporedu: - Primarno cepljenje s Proteqflu-TE: prvi odmerek pri starosti petih do šestih mesecev, drugi odmerek 4 do 6 tednov pozneje.
Intramuscular use. 
Intramuskularno dajanje.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Outer package for 10 doses: 10 vials of 1 dose 
PODATKI NA ZUNANJI OVOJNINI Zunanja ovojnina za 10 odmerkov suspenzije
4.9 Amounts to be administered and administration route 
4.9 Odmerjanje in način uporabe
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK
MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALCI BIOLOŠKIH ZDRAVILNIH UČINKOVIN IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY OR USE 
B. POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE IN UPORABE
The vaccine strains vCP2242 and vCP3011 are recombinant canarypox viruses expressing the haemagglutinin HA gene from the equine influenza virus strains A/eq/Ohio/03 (American strain, Florida sublineage clade 1) and A/eq/Richmond/1/07 (American strain, Florida sublineage clade 2), respectively. 
Seva cepiva vCP3011 in vCP2242 sta rekombinantna canarypox virusa, ki izražata hemaglutinin HA gen sevov A/eq/Ohio/03 (ameriški sev, podvrsta Florida 1) in A/eq/Richmond/1/07 (ameriški sev, podvrsta Florida 2) virusa konjske influence.
SPECIAL WARNING(S) 
POSEBNO(A) OPOZORIL(O)A
ProteqFlu-Te suspension for injection for horses 
ProteqFlu-Te suspenzija za injiciranje za konje
Butyl elastomer closure and aluminium cap. 
Viala iz stekla tipa I Zamašek iz butilnega elastomera in aluminijska zaporka za vialo.
Influenza A/eq/Ohio/03 [H3N8] (vCP2242) ............................................................. ≥ 5.3 log10 FAID50 Influenza A/eq/Richmond/1/07 [H3N8] (vCP3011) .................................................. ≥ 5.3 log10 FAID50 Clostridium tetani toxoid ............................................................................................................. ≥ 30 IU 
Influenza A/eq/Ohio/03 [H3N8] (vCP2242) .............................................................. ≥ 5,3 log10 FAID50 Influenza A/eq/Richmond/1/07 [H3N8] (vCP3011) ................................................... ≥ 5,3 log10 FAID50 Clostridium tetani toksoid.
Influenza A/eq/Ohio/03 [H3N8] recombinant canarypox virus (vCP2242) ............ ≥ 5.3 log10 FAID50* Influenza A/eq/Richmond/1/07 [H3N8] recombinant canarypox virus (vCP3011) . 
Influenza A/eq/Ohio/03 [H3N8] rekombinantni Canarypox virus (vCP2242) .......... ≥ 5,3 log10 FAID50* Influenza A/eq/Richmond/1/07 [H3N8] rekombinantni
Duration of immunity induced by the vaccination scheme: - 5 months after the primary vaccination course; - after the primary vaccination course and the booster injection 5 months later: 1 year with regard to equine influenza and 2 years with regard to tetanus. 
- Po primarnem cepljenju in poživitvenem cepljenju čez 5 mesecev: 1 leto za influenco konj in 2
• Keep out of the sight and reach of children. 
• Zdravilo shranjujte nedosegljivo otrokom.
Influenza A/eq/Ohio/03 [H3N8] recombinant Canarypox virus (vCP2242) ........... ≥ 5.3 log10 FAID50* Influenza A/eq/Richmond/1/07 [H3N8] recombinant Canarypox virus (vCP3011) ≥ 5.3 log10 FAID50* Clostridium tetani toxoid ......................................................................................................... ≥ 30 IU** 
Influenza A/eq/Ohio/03 [H3N8] rekombinantni Canarypox virus (vCP2242) .......... ≥ 5,3 log10 FAID50* Influenza A/eq/Richmond/1/07 rekombinantni Canarypox virus (vCP3011) .......... ≥ 5,3 log10 FAID50* Clostridium tetani toksoid.
o against equine influenza: injection of 1 dose every year, alternatively with ProteqFlu or ProteqFlu-Te, respecting an interval of maximum 2 years for the tetanus component. 
• Nadaljnje cepljenje: o Proti tetanusu: 1 odmerek Proteqflu TE največ vsaki dve leti o Proti influenci konj: 1 odmerek vsako leto, izmenjaje Proteqflu in Proteqflu TE,
EXP 
Rp-Vet.
No interaction has been observed when the vaccine was administered simultaneously, but at a separate site, with MERIAL's inactivated vaccine against rabies. 
Pri sočasnem dajanju cepiva, vendar na različnih mestih niso ugotovili nobenih interakcij, z
PACKAGE LEAFLET FOR: ProteqFlu-Te suspension for injection for horses 
NAVODILO ZA UPORABO ProteqFlu-Te suspenzija za injiciranje za konje.
Date of first authorisation: 16 January 2014 Date of latest renewal: 28 September 2018 
Datum prve odobritve: 16. januar 2014 Datum zadnjega podaljšanja: 28. september 2018
It can also help prevent heart disease. 
Pomaga lahko tudi preprečiti srčno bolezen.
Results at Week 24 (LOCF 
Rezultati po 24 tednih (LOCF
• Take your tablet twice daily, once in the morning (breakfast) and once in the evening (dinner). 
• Tableto vzemite dvakrat na dan, enkrat zjutraj (zajtrk) in enkrat zvečer (večerja).
• if you have ever had a diabetic coma. 
• če ste kdaj imeli diabetično komo.
The events occurred evenly distributed over the study period. 
Primeri so bili enakomerno porazdeljeni skozi obdobje študije.
Frequency is based on annual rate. 
Pogostnost temelji na podlagi letnega deleža.
Time to first event was analysed in a Cox proportional hazards model. 
Čas do prvega dogodka je bil analiziran s Coxovim modelom sorazmernih ogroženosti.
Consumption of alcohol and medicinal products containing alcohol should be avoided. 
Izogibati se je treba uživanju alkohola ali zdravil, ki vsebujejo alkohol.
These effects were sustained in longer-term trials. 
Ti učinki so se ohranili v dolgoročnejših preskušanjih.
The mean age of the study population was 63.9 years, 37.4% were female. 
Povprečna starost študijske populacije je bila 63,9 leta in 37,4 % je bilo žensk.
• awakening from sleep at night to pass urine 
• prebujanje ponoči, da bi šli na vodo
LOCF: last observation (prior to rescue for rescued patients) carried forward. 
LOCF: prenos zadnjega opažanja (pred rešilnim zdravljenjem za rešene bolnike) [Last Observation Carried Forward].
Your doctor may ask you to stop taking this medicine. 
Zdravnik vam lahko naroči, da nehajte jemati to zdravilo.
Take the medicine pack with you. 
S seboj vzemite škatlico zdravila.
Your doctor will tell you exactly which strength of this medicine to take. 
Zdravnik vam bo natančno povedal, katero jakost tega zdravila morate jemati.
This medicine is not recommended for children and adolescents under 18 years of age, because it has not been studied in these patients. 
Uporaba tega zdravila ni priporočljiva pri otrocih in mladostnikih, starih manj kot 18 let, ker pri teh bolnikih zdravilo ni bilo raziskano.
Patients at risk is the number of patients at risk at the beginning of the period. 
Podatek o številu bolnikov, izpostavljenih tveganju, pomeni število bolnikov, izpostavljenih tveganju na začetku obdobja.
If you miss a dose, take it as soon as you remember. 
Če ste pozabili vzeti odmerek, ga vzemite takoj, ko se spomnite.
The number of first events for the single components are the actual number of first events for each component and does not add up to the number of events in the composite endpoint. 
Števila prvih dogodkov posameznih elementov so dejanska števila prvih dogodkov za vsak element in se ne seštejejo v število dogodkov v sestavljenem opazovanem dogodku.
• if you have a severe infection. 
• če imate hudo okužbo.
Results on primary and secondary endpoints are displayed in Figure 2. 
Rezultati o primarnih in sekundarnih opazovanih dogodkih so prikazani na sliki 2.
• changes in taste 
• spremembe okusa
The safety and efficacy of Xigduo in children and adolescents aged 0 to < 18 years have not yet been established. 
Varnost in učinkovitost zdravila Xigduo pri otrocih in mladostnikih v starosti od 0 do < 18 let nista ugotovljeni.
Do not take this medicine if any of the above apply to you. 
Ne jemljite tega zdravila, če kar koli od navedenega velja za vas.
Body weight reductions were sustained in long-term extensions up to 208 weeks. 
Zmanjšanje telesne mase se je ohranilo v dolgoročnih podaljšanjih do 208 tednov.
Elderly (≥ 65 years) 
Starejši (stari 65 let ali več)
• Take your tablet with food. 
• Tableto vzemite s hrano.
This is to reduce the risk of side effects in the stomach. 
Tako boste zmanjšali tveganje za neželene učinke v želodcu.
A GFR should be assessed before initiation of treatment with metformin containing medicinal products and at least annually thereafter. 
GFR je treba oceniti pred uvedbo zdravljenja z zdravili, ki vsebujejo metformin, nato pa vsaj enkrat letno.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient's clinical status. 
V primeru prevelikega odmerjanja je treba uvesti ustrezno podporno zdravljenje, kot ga narekuje bolnikovo klinično stanje.
< 30 Metformin is contraindicated. 
< 30 Metformin je kontraindiciran.
• if you are taking medicines which increase urine production (diuretics). 
• če jemljete zdravila, ki povečujejo nastajanje urina (diuretike).
All randomised patients who took at least one dose of double-blind study medicinal product during the shortterm double-blind period. 
Vsi randomizirani bolniki, ki so prejeli vsaj en odmerek dvojno slepljenega raziskovanega zdravila med kratkoročnim dvojno slepim obdobjem.
This effect was observed at Week 1 of treatment and maintained in studies extended through Week 104. 
Ta učinek je bil opazen 1. teden zdravljenja in se je ohranil v študijah, podaljšanih do 104. tedne.
It is important to check your feet regularly and adhere to any other advice regarding foot care given by your health care professional. 
Pomembno je, da si redno pregledujete stopala in upoštevate ostale nasvete o negi stopal, ki ste jih prejeli od zdravstvenega delavca.
• Prior to initiation of concomitant medicinal products that may reduce renal function and periodically thereafter. 
• Pred uvedbo sočasnih zdravil, ki lahko zmanjšajo delovanje ledvic, in redno pozneje.
The mean Vd ranged between 63-276 l. 
Povprečni Vd je bil med 63 in 276 l.
None were found to be dose-related. 
Za nobenega ni bilo ugotovljeno, da bi bil povezan z odmerkom.
Similar reductions were observed at up to 104 weeks. 
Po obdobju do 104 tedne so opažali podobna znižanja.
Dapagliflozin is approximately 91% protein bound. 
Dapagliflozin je približno 91-odstotno vezan na beljakovine.
Do not drive or use any tools or machines, if you start to feel these symptoms. 
Ne upravljajte vozil in strojev, če se vam začnejo pojavljati ti simptomi.
After administration of a 50 mg [ 
Po uporabi odmerka 50 mg [
Both belong to a group of medicines called oral anti-diabetics. 
Obe spadata v skupino zdravil, ki jih imenujemo peroralni antidiabetiki.
(95% CI) Difference from metformin c 
(95 % IZ) Razlika od metformina c
Component of a multipack, can't be sold separately. 
Del skupnega pakiranja, ni za ločeno prodajo.
The red blood cells most likely represent a secondary compartment of distribution. 
Eritrociti najverjetneje predstavljajo sekundarni razdelek porazdelitve.
Do not stop taking this medicine without talking to your doctor first. 
Ne prenehajte jemati tega zdravila, ne da bi se prej posvetovali z zdravnikom.
• if you have recently had a heart attack or if you have heart failure or serious problems with your blood circulation or difficulties in breathing. 
• če ste nedavno imeli srčni infarkt, če imate srčno popuščanje ali hude težave s krvnim obtokom ali težave z dihanjem.
• if you drink large amounts of alcohol, either every day or only from time to time (please see section “Xigduo with alcohol”). 
• če pijete veliko alkohola (vsak dan ali le od časa do časa) (glejte poglavje "Zdravilo Xigduo skupaj z alkoholom").
Biotransformation Metformin is excreted unchanged in the urine. 
Biotransformacija Metformin se nespremenjen izloči v urinu.
In total, 22.4% had had diabetes for ≤ 5 years, mean duration of diabetes was 11.9 years. 
V celoti jih je 22,4 % imelo sladkorno bolezen ≤ 5 let, povprečno trajanje sladkorne bolezni je bilo 11,9 leta.
• Before initiation of treatment and regularly thereafter (see sections 4.2, 4.8, 5.1 and 5.2). 
• Pred uvedbo zdravljenja in redno po njej (glejte poglavja 4.2, 4.8, 5.1 in 5.2).
Therefore, the use of this medicinal product is not recommended during the second and third trimesters of pregnancy. 
Zato tega zdravila ni priporočljivo uporabljati v drugem in tretjem trimesečju nosečnosti.
• decreased vitamin B12 levels in the blood 
• zmanjšana koncentracija vitamina B12 v krvi
• This medicine is taken in combination with diet and exercise. 
• To zdravilo morate jemati v kombinaciji z dieto in telesno dejavnostjo.
Measure your blood sugar if possible and rest. 
Če je le mogoče, si izmerite vrednost sladkorja v krvi in počivajte.
Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away (see section 2). 
Takoj nehajte jemati to zdravilo in nemudoma obvestite zdravnika ali najbližjo bolnišnico (glejte poglavje 2).
Frequency categories are defined according to the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), and not known (cannot be estimated from the available data). 
Kategorije pogostnosti so opredeljene po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana (ni mogoče oceniti iz razpoložljivih podatkov).
This medicine may cause urinary tract infections and your doctor may want to monitor you more closely. 
To zdravilo lahko povzroči okužbe sečil in zdravnik vas bo morda želel natančneje kontrolirati.
Clinically relevant glycaemic effects were sustained in long-term extensions up to 104 weeks. 
Klinično pomembni učinki na glikemijo so se ohranili v dolgoročnih podaljšanjih do 104 tedne.
In faeces, approximately 15% of the dose was excreted as parent drug. 
V blatu se je približno 15 % odmerka izločilo kot matično zdravilo.
HR=Hazard ratio CI=Confidence interval. 
HR = razmerje ogroženosti ("Hazard ratio") IZ = interval zaupanja.
If acidosis of either form occurs, treatment must be stopped immediately and other appropriate corrective measures initiated. 
Če se pojavi kakršna koli oblika acidoze, je treba zdravljenje nemudoma prekiniti in uvesti ustrezne korektivne ukrepe.
Adverse reactions listed below are classified according to frequency and system organ class. 
Spodaj našteti neželeni učinki so razvrščeni po pogostnosti in organskem sistemu.
• For renal function with GFR levels < 60 mL/min and in elderly patients, at least 2 to 4 times per year. 
• V primeru delovanja ledvic z GFR < 60 ml/min in pri starejših bolnikih, vsaj 2- do 4-krat na leto.
A limited amount of data from the use of metformin in pregnant women does not indicate an increased risk of congenital malformations. 
Maloštevilni podatki uporabe metformina pri nosečnicah ne kažejo večjega tveganja za prirojene malformacije.
The patient should be informed and more frequent blood glucose monitoring perfomed, especially at the beginning of treatment with such medicinal products. 
Bolnika je treba s tem seznaniti in potrebne so pogostejše kontrole glukoze v krvi, zlasti na začetku zdravljenja s takšnimi zdravili.
The renal composite endpoint and all-cause mortality were therefore not tested as part of the confirmatory testing procedure. 
Ledvični sestavljeni opazovani dogodek in umrljivost zaradi vseh vzrokov zato nista bila testirana kot del postopka potrditvenega testiranja.
• if you are allergic to dapagliflozin, metformin or any of the other ingredients of this medicine (listed in section 6). 
• če ste alergični na dapagliflozin, metformin ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Ketoacidosis is a condition in which substances called ‘ketone bodies' accumulate in the blood and which can lead to a diabetic pre-coma. 
Ketoacidoza je stanje, pri katerem se snovi, imenovane 'ketonska telesa', kopičijo v krvi, kar lahko povzroči diabetično predkomo.
See corresponding subsection below for additional information. 
Za dodatne informacije glejte ustrezno podpoglavje spodaj.
• The recommended dose is one tablet twice a day. 
• Priporočeni odmerek je ena tableta dvakrat na dan.
Your doctor will check your kidney function. 
Zdravnik vam bo preveril delovanje ledvic.
P-values are all adjusted p-values for multiplicity. 
Vse vrednosti p so vrednosti p, prilagojene za večkratno testiranje.
Xigduo is contraindicated in patients with: 
Zdravilo Xigduo je kontraindicirano pri bolnikih s:
To treat diabetes: 
Zdravljenje sladkorne bolezni:
Figure 2: Treatment effects for the primary composite endpoints and their components, and the secondary endpoints and components 
Slika 2: Terapevtski učinki glede primarnih sestavljenih opazovanih dogodkov in njihovih elementov ter sekundarnih opazovanih dogodkov in njihovih elementov
p-values for the secondary endpoints and for single components are nominal. 
Vrednosti p za sekundarna opazovana dogodka in za posamezne elemente so nominalne.
More information is given below under ‘Other medicines and Xigduo'. 
Več informacij najdete v poglavju "Druga zdravila in zdravilo Xigduo", spodaj.
p-values are two-sided. 
Vrednosti p so dvostranske.
• The amount of this medicine that you will take varies depending on your condition and the doses you currently take of metformin and/or individual tablets of dapagliflozin and metformin. 
• Koliko tega zdravila boste jemali, bo odvisno od vašega stanja in od tega, kolikšne odmerke metformina in/ali posameznih tablet dapagliflozina in metformina trenutno jemljete.
If you have symptoms of low blood sugar, eat glucose tablets, a high sugar snack or drink fruit juice. 
Če imate simptome nizkega krvnega sladkorja, pojejte tablete z glukozo, prigrizek, ki vsebuje veliko sladkorja, ali popijte sadni sok.
The following statements reflect the pharmacokinetic properties of the individual active substances of this medicinal product. 
Naslednje navedbe temeljijo na farmakokinetičnih lastnostih posameznih učinkovin tega zdravila.
The recommended dose is one tablet twice daily. 
Priporočeni odmerek je ena tableta 2-krat na dan.
Monitoring of renal function: 
Spremljanje delovanja ledvic:
CI=confidence interval. 
IZ = interval zaupanja
The safety and efficacy of Xigduo in patients with type 1 diabetes have not been established and Xigduo should not be used for treatment of patients with type 1 diabetes. 
Varnost in učinkovitost zdravila Xigduo pri bolnikih s sladkorno boleznijo tipa 1 nista ugotovljeni in zdravila Xigduo se ne sme uporabljati za zdravljenje takšnih bolnikov.
This leads to a high level of sugar (glucose) in your blood. 
Posledica je visoka koncentracija sladkorja (glukoze) v krvi.
Do not use this medicine after the expiry date which is stated on the blister or carton after ‘EXP'. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu ali škatli poleg oznake "EXP".
The maximum daily dose of metformin should preferably be divided into 2-3 daily doses. 
Zaželeno je, da se največji dnevni odmerek metformina razdeli v 2 do 3 dnevne odmerke.
Paediatric population Pharmacokinetics in the paediatric population have not been studied. 
Pediatrična populacija Farmakokinetika pri pediatrični populaciji ni raziskana.
Metformin increases the transport capacity of specific types of membrane glucose transporters (GLUT-1 and GLUT-4). 
Metformin poveča prenašalno kapaciteto specifičnih vrst membranskih prenašalcev glukoze (GLUT-1 in GLUT-4).